Key result
ACE and ACTN3 gene variants show no association with power or endurance athletic performance.
Why the study?
Conflicting data exist regarding the association of genomic variants with athletic performance such as endurance, speed, and strength.
Do genomic variants (ACE Alu I/D and ACTN3 p.R577X) predict athletic performance in power and endurance sports?
Meta-Analysis (n=54,382)
Do genomic variants (ACE Alu I/D and ACTN3 p.R577X) predict athletic performance in power and endurance sports?
Answers are grounded in this paper and cite their sources.
No association with ACE/ACTN3 variants; challenges direct-to-consumer genetic testing for sports talent identification.
Association between genomic variants and athletic performance has seen a high degree of controversy, as there is often conflicting data as far as the association of genomic variants with endurance, speed and strength is concerned. Here, findings from a thorough meta-analysis from 4228 articles exploring the association of genomic variants with athletic performance in power and endurance sports are summarized, aiming to confirm or overrule the association of genetic variants with athletic performance of all types. From the 4228 articles, only 107 were eligible for further analysis, including 37 different genes. From these, there were 21 articles for the ACE gene, 29 articles for the ACTN3 gene and 8 articles for both the ACE and ACTN3 genes, including 54,382 subjects in total, from which 11,501 were endurance and power athletes and 42,881 control subjects. These data show that there is no statistically significant association between genomic variants and athletic performance either for endurance or power sports, underlying the fact that it is highly risky and even unethical to make such genetic testing services for athletic performance available to the general public. Overall, a strict regulatory monitoring should be exercised by health and other legislative authorities to protect the public from such services from an emerging discipline that still lacks the necessary scientific evidence and subsequent regulatory approval.
No takes yet. Share an insight, caveat, or question.
Psatha et al. (2024) conducted a meta-analysis in Athletic performance (n=54,382). ACE Alu I/D and ACTN3 p.R577X genomic variants vs. Non-athlete controls was evaluated on Association of ACE II + ID versus ACE DD genotypes with athletic performance (power and endurance athletes versus controls) (OR 1.189, 95% CI 0.728-1.946, p=0.956). Genomic variants in the ACE and ACTN3 genes showed no statistically significant association with athletic performance in either endurance or power sports.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: